Helicobacter pylori infection
Conditions
Interventions
Group A:Vonoprazan 20 mg twice daily (bid) , Amoxicillin 1.0 g twice daily (bid), Metronidazole 0.4 g three times daily (tid), Bismuth Potassium Citrate Capsules 0.6 g twice daily
treatment duration: 7 days.
Group B:Vonoprazan 20 mg twice daily (bid) , Amoxicillin 1.0 g twice daily (bid), Metronidazole 0.4 g three times daily (tid), Bismuth Potassium Citrate Capsules 0.6 g twice daily
treatment duration: 10days.
Group C:Vonoprazan 20 mg twice daily (bid) , Amoxicillin 1.0 g twice daily (bid), Metronidazole 0.4 g three times daily (tid), Bismuth Potassium Citrate Capsules 0.6 g twice daily
treatment duration: 14days.
Control Group:Esomeprazole Magnesium Enteric-Coated Capsules 20 mg twice daily (bid) + Amoxicillin 1.0 g twice daily (bid), Metronidazole 0.4 g three times daily (tid), Bismuth Potassium Citrate Capsu
treatment duration: 14 days.
Sponsors
The Fourth Central Hospital of Tianjin
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Positive Hp infection confirmed by 13C or 14Cbreath test 2. Age 18-70 years; 3.Initial treatment of patients
Exclusion criteria
Exclusion criteria: 1. Those who have used antibiotics, bismuth agents,non-steroidal anti-inflammatory drugs or Chinese herbal medicines with antibacterial properties within one month; those who have used acid inhibitors within two weeks before HP eradication therapy; 2. Active peptic ulcer, accompanied by complications such as bleeding, perforation, obstruction and canceration; 3. History of esophageal or gastrectomy surgery; 4.Allergy to penicillin** or any other study medications. 5. Suffering from serious underlying diseases (heart, lungs, brain, liver, kidneys, etc.), suffering from malignant tumors or other diseases; 5. Pregnant or lactating women; 6. Participate in other research within three months and be unable to express one's own ideas correctly or cooperate with the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of adverse events;Economic benefit; | — |
Countries
China
Contacts
Public ContactJing Zhang
The Fourth Central Hospital of Tianjin
Outcome results
None listed